Kura Oncology Reports Fourth Quarter and Full Year 2020 Financial Results
24 févr. 2021 07h20 HE
|
Kura Oncology, Inc.
– Preliminary clinical data for menin inhibitor KO-539 highlighted by single-agent activity in relapsed/refractory AML, including patients with NPM1 mutations – – KO-539 continues to demonstrate a...
Kura Oncology Receives FDA Breakthrough Therapy Designation for Tipifarnib in Head and Neck Squamous Cell Carcinoma
24 févr. 2021 07h00 HE
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Participate in Four Upcoming Investor Conferences
18 févr. 2021 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Report Fourth Quarter and Full Year 2020 Financial Results
17 févr. 2021 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Participate in H.C. Wainwright BioConnect 2021 Conference
07 janv. 2021 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Present at J.P. Morgan Healthcare Conference
06 janv. 2021 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
11 déc. 2020 16h05 HE
|
Kura Oncology, Inc.
SAN DIEGO, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Participate in the JMP Securities Hematology Summit
10 déc. 2020 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Presents First Clinical Data for Menin Inhibitor KO-539 at American Society of Hematology Annual Meeting
05 déc. 2020 12h30 HE
|
Kura Oncology, Inc.
– Evidence of biologic activity observed in each dose-escalation cohort treated to date – – Clinical activity includes one CR in a patient with a NPM1 mutation and one CR in a patient with a...
Kura Oncology to Participate in Three Upcoming Investor Conferences
04 nov. 2020 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...